Suppr超能文献

比较调强放疗中不同化疗序列在晚期 N 期鼻咽癌患者中的治疗效果。

Comparing treatment outcomes of different chemotherapy sequences during intensity modulated radiotherapy for advanced N-stage nasopharyngeal carcinoma patients.

机构信息

State Key Laboratory of Oncology in Southern China, Guanggzhou, PR China.

出版信息

Radiat Oncol. 2013 Nov 13;8:265. doi: 10.1186/1748-717X-8-265.

Abstract

BACKGROUND

N-stage is related to distant metastasis of nasopharyngeal carcinoma (NPC) patients. We performed this study to compare the efficacy of different chemotherapy sequences in advanced N-stage (N2 and N3) NPC patients treated with intensity modulated radiotherapy (IMRT).

METHODS

From 2001 to 2008, 198 advanced N-stage NPC patients were retrospectively analyzed. Thirty-three patients received IMRT alone. Concurrent chemoradiotherapy (CCRT) was delivered to 72 patients, neoadjuvant chemotherapy (NACT) + CCRT to 82 patients and CCRT + adjuvant chemotherapy (AC) to 11 patients.

RESULTS

The 5-year overall survival rate, recurrence-free survival rate, distant metastasis-free survival rate and progress-free survival rate were 47.7% and 73.1%(p<0.001), 74.5% and 91.3% (p = 0.004), 49.2% and 68.5% (p = 0.018), 37.5% and 63.8% (p<0.001) in IMRT alone and chemoradiotherapy group. Subgroup analyses indicated that there were no significant differences among the survival curves of CCRT, NACT + CCRT and CCRT + AC groups. The survival benefit mainly came from CCRT. However, there was only an improvement attendency in distant metastasis-free survival rate of CCRT group (p = 0.107) when compared with RT alone group, and NACT + CCRT could significantly improve distant metastasis-free survival (p = 0.017).

CONCLUSIONS

For advanced N-stage NPC patients, NACT + CCRT might be a reasonable treatment strategy.

摘要

背景

N 分期与鼻咽癌(NPC)患者的远处转移有关。我们进行这项研究是为了比较调强放疗(IMRT)治疗中晚期 N 分期(N2 和 N3)NPC 患者时,不同化疗顺序的疗效。

方法

回顾性分析 2001 年至 2008 年收治的 198 例晚期 N 分期 NPC 患者。33 例患者接受单纯 IMRT,72 例患者接受同期放化疗(CCRT),82 例患者接受新辅助化疗(NACT)+CCRT,11 例患者接受 CCRT+辅助化疗(AC)。

结果

单纯 IMRT 组和放化疗组的 5 年总生存率、无复发生存率、无远处转移生存率和无进展生存率分别为 47.7%和 73.1%(p<0.001)、74.5%和 91.3%(p=0.004)、49.2%和 68.5%(p=0.018)、37.5%和 63.8%(p<0.001)。亚组分析显示,CCRT、NACT+CCRT 和 CCRT+AC 组的生存曲线无显著差异。生存获益主要来自 CCRT,但与单纯 RT 组相比,CCRT 组仅显示出无远处转移生存率的改善趋势(p=0.107),而 NACT+CCRT 可显著提高无远处转移生存率(p=0.017)。

结论

对于晚期 N 分期 NPC 患者,NACT+CCRT 可能是一种合理的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d3d/3842780/a7f00e229451/1748-717X-8-265-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验